- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Sep 6, 2024
Distillery Therapeutics
Inhibiting CDA for checkpoint inhibitor-resistant cancers
BioCentury | Feb 7, 2020
Translation in Brief
Gilead’s remdesivir vs. 2019-nCov in cells; plus Syndax, Syntrix and Max Planck
BioCentury's roundup of preclinical news
BioCentury | Jan 17, 2020
Targets & Mechanisms
CPSF3 emerges as new synthetic lethality target in AML and sarcoma
NIBR identifies CPSF3 as novel synthetic lethality target in subsets of AML, sarcoma
BioCentury | Oct 15, 2019
Finance
Cyteir synthetic lethality compound prompts Novo to lead $40M investment
Cyteir is Novo Holdings’ first investment in the DNA damage repair space
Items per page:
1 - 10 of 37